Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …

Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of
Bruton's tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell …

In recent years, advancements in the treatment of hematologic neoplasms have led to more
effective and less toxic therapeutic schemes, resulting in prolonged patient life expectancy …

Aims The sympathetic nervous system increases HR by activating β-adrenergic receptors (β-
ARs) and increasing cAMP in sinoatrial node (SAN) myocytes while phosphodiesterases …

Cardiac arrhythmias remain a significant concern with Ibrutinib (IBR), a first-generation
Bruton's tyrosine kinase inhibitor (BTKi). Acalabrutinib (ABR), a next-generation BTKi, is …

Whether ibrutinib-related atrial fibrillation (IRAF) is a dose-dependent adverse drug reaction
(ADR) and whether ibrutinib should be discontinued or dose-reduced in case of IRAF …

Introduction The first-in-class Bruton tyrosine kinase (BTK), ibrutinib, demonstrated
remarkable activity in chronic lymphocytic leukemia (CLL). However, its toxicity profile …

COI notes: MJR reports personal fees from Apotex, Aptevo, Arvinas Operations, Ayala
Pharma, Bayer Pharmaceuticals, bluebird bio, Credit Suisse, Eagle Pharmaceuticals, EMD …

Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the
proliferation and survival pathway of neoplastic B‐cells. BTK inhibitors are approved in …

Background: Ibrutinib could increase the risk of atrial fibrillation (AF) in chronic lymphocytic
leukemia (CLL) patients. However, the precise mechanism underlying ibrutinib-induced AF …